Gilead's Yescarta shows consistent real-world survival outcomes regardless of race
seekingalpha.com
finance
2022-06-03 20:24:23

luismmolina/iStock via Getty Images Gilead Sciences' (NASDAQ:GILD) Kite on Friday announced findings from an analysis of race and ethnicity from its ongoing post-authorization study of Yescarta in adults with large B-cell lymphoma (LBCL), a type of cancer in white blood cells called lymphocytes. The real-world analysis showed overall outcomes including overall survival and progression-free survival rates were consistent with Yescarta in the real-world setting, regardless of race and ethnicity. The findings also found that Black or African American patients experience longer time from diagnosis to infusion vs.
